Literature DB >> 24193364

Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al.

Davide Campana1, Gianfranco Delle Fave, Massimo Falconi, Paola Tommassetti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24193364     DOI： 10.1007/s00259-013-2603-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  11 in total

1.  TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; A Couvelard; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2007-08-03       Impact factor: 4.064

2.  Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.

Authors:  Francesco Panzuto; Silvia Nasoni; Massimo Falconi; Vito Domenico Corleto; Gabriele Capurso; Sara Cassetta; Michela Di Fonzo; Valentina Tornatore; Massimo Milione; Stefano Angeletti; Maria Sofia Cattaruzza; Vincenzo Ziparo; Cesare Bordi; Paolo Pederzoli; Gianfranco Delle Fave
Journal:  Endocr Relat Cancer       Date:  2005-12       Impact factor: 5.678

3.  Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors.

Authors:  Francesco Panzuto; Davide Campana; Nicola Fazio; Maria Pia Brizzi; Letizia Boninsegna; Francesca Nori; Giovanni Di Meglio; Gabriele Capurso; Aldo Scarpa; Luigi Dogliotti; Filippo De Braud; Paola Tomassetti; Gianfranco Delle Fave; Massimo Falconi
Journal:  Neuroendocrinology       Date:  2011-12-28       Impact factor: 4.914

4.  Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.

Authors:  Francesco Panzuto; Letizia Boninsegna; Nicola Fazio; Davide Campana; Maria Pia Brizzi; Gabriele Capurso; Aldo Scarpa; Filippo De Braud; Luigi Dogliotti; Paola Tomassetti; Gianfranco Delle Fave; Massimo Falconi
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

5.  Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.

Authors:  Anna Imhof; Philippe Brunner; Nicolas Marincek; Matthias Briel; Christian Schindler; Helmut Rasch; Helmut R Mäcke; Christoph Rochlitz; Jan Müller-Brand; Martin A Walter
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

6.  Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients.

Authors:  Aldo Scarpa; William Mantovani; Paola Capelli; Stefania Beghelli; Letizia Boninsegna; Rossella Bettini; Francesco Panzuto; Paolo Pederzoli; Gianfranco delle Fave; Massimo Falconi
Journal:  Mod Pathol       Date:  2010-03-19       Impact factor: 7.842

7.  Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours.

Authors:  R Bettini; L Boninsegna; W Mantovani; P Capelli; C Bassi; P Pederzoli; G F Delle Fave; F Panzuto; A Scarpa; M Falconi
Journal:  Ann Oncol       Date:  2008-01-21       Impact factor: 32.976

8.  Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.

Authors:  Davide Campana; Gabriele Capurso; Stefano Partelli; Francesca Nori; Francesco Panzuto; Domenico Tamburrino; Giulia Cacciari; Gianfranco Delle Fave; Massimo Falconi; Paola Tomassetti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-26       Impact factor: 9.236

9.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

Authors:  Dik J Kwekkeboom; Wouter W de Herder; Boen L Kam; Casper H van Eijck; Martijn van Essen; Peter P Kooij; Richard A Feelders; Maarten O van Aken; Eric P Krenning
Journal:  J Clin Oncol       Date:  2008-05-01       Impact factor: 44.544

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.